Physician profile
Danny Bronshtein
NPI 1417489188
$4,483.20
in general payments reported to CMS, 2019-2025
23 companies · $1,866 in 2025
The $1,866 reported for 2025 was more than what 95% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $514 · 2022: $522 · 2023: $546 · 2024: $1,035 · 2025: $1,866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,963 · Consulting Fee: $300 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,963.35 |
| Consulting Fee | $300.00 |
| Education | $183.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $642.51 | 2021-2025 | Dupixent |
| Arcutis Biotherapeutics, INC. | $623.35 | 2024-2025 | Zoryve |
| Incyte Corporation | $594.27 | 2021-2025 | Opzelura |
| Abbvie INC. | $435.38 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $406.51 | 2021-2025 | |
| Amgen INC. | $358.28 | 2021-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $218.34 | 2023-2025 | Tremfya |
| Genzyme Corporation | $198.81 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $172.82 | 2021-2025 | |
| Verrica Pharmaceuticals INC. | $159.71 | 2024-2025 | Ycanth |
| Lilly USA, LLC | $92.89 | 2021-2025 | Ebglyss, Taltz |
| Pfizer INC. | $87.55 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $84.52 | 2021-2025 | |
| Galderma Laboratories, L.P. | $70.57 | 2022-2023 | |
| Vyne Pharmaceuticals INC. | $64.62 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Botanix Sb INC | $61.38 | 2025 | Sofdra |
| Leo Pharma INC. | $55.96 | 2025 | Adbry, Anzupgo |
| Lnhc, INC | $47.30 | 2025 | Zelsuvmi |
| Dermavant Sciences, INC. | $26.37 | 2022 | |
| Organon LLC | $24.18 | 2025 | Vtama |
| Smith+Nephew, INC. | $22.77 | 2022 | |
| Journey Medical Corporation | $19.51 | 2025 | |
| Dermira, INC. | $15.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danny Bronshtein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.